IRME · As filed with the SEC

IR-Med cash flow statement, by quarter

The statement as IR-Med presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) · USD thousands

USD thousands	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024^† 3 months ended Sep 30, 2024
Cash flows from operating activities
Net Income	(701)^†	(773)	(278)^†	(598)^†
Adjustments to reconcile loss for the period to net cash used in operating activities:
Total stock-based compensation	87^†	54	(18)^†	197^†
Depreciation Expense	4^†	3	4^†	4^†
Non-cash financial expenses (income)	413^†	520	—	—
Decrease in accounts receivable	3^†	46	(24)^†	(15)^†
Change in Accounts Payable	(50)^†	40	57^†	10^†
Net cash used in operating activities	(71)^†	(110)	(261)^†	(395)^†
Cash flows from financing activities
Proceeds from Debt Issuance	0^†	39	—	—
Repayment of short-term loan	—	(39)	0^†	—
Proceeds from Debt Issuance	0^†	31	—	—
Net Cash from Financing Activities	—	—	0^†	40^†
Net cash provided by financing activities	88^†	31	0^†	35^†
Effect of Exchange Rate on Cash	(5)^†	1	—	—
Net decrease in cash and cash equivalents	12^†	(78)	(263)^†	(361)^†
Cash and cash equivalents as at the beginning of the period	51	129	392	753
Cash and cash equivalents as at the end of the period	63	51	129	392

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.